written on 27.02.2014

INTERVIEW: Oncology central as Takeda extends global reach


With multiple myeloma drug Velcade (bortezomib) already generating substantial revenues and enrollment underway in more than 10 Phase III trials with other projects, it is an effort that seems to be paying dividends and one that Dr Michael Vasconcelles…